An expanded toolkit of drug resistance cassettes for Candida glabrata, Candida auris, and Candida albicans leads to new insights into the ergosterol pathway

mSphere. 2023 Dec 20;8(6):e0031123. doi: 10.1128/msphere.00311-23. Epub 2023 Nov 6.

Abstract

The increasing problem of drug resistance and emerging pathogens is an urgent global health problem that necessitates the development and expansion of tools for studying fungal drug resistance and pathogenesis. Prior studies in Candida glabrata, Candida auris, and Candida albicans have been mainly limited to the use of NatMX/SAT1 and HphMX/CaHyg for genetic manipulation in prototrophic strains and clinical isolates. In this study, we demonstrated that NatMX/SAT1, HphMX, KanMX, and/or BleMX drug resistance cassettes when coupled with a CRISPR-ribonucleoprotein (RNP)-based system can be efficiently utilized for deleting or modifying genes in the ergosterol pathway of C. glabrata, C. auris, and C. albicans. Moreover, the utility of these tools has provided new insights into ERG genes and their relationship to azole resistance in Candida. Overall, we have expanded the toolkit for Candida pathogens to increase the versatility of genetically modifying complex pathways involved in drug resistance and pathogenesis.

Keywords: CRISPR-RNP; Candida albicans; Candida auris; Candida glabrata; ERG5 and ERG3; KanMX and BleMX; antifungal drug resistance; azole antifungal drugs; ergosterol pathway; toxic sterols.

MeSH terms

  • Antifungal Agents / metabolism
  • Antifungal Agents / pharmacology
  • Candida / genetics
  • Candida albicans* / genetics
  • Candida auris
  • Candida glabrata*
  • Drug Resistance, Fungal / genetics
  • Ergosterol

Substances

  • Antifungal Agents
  • Ergosterol